AMENDMENTS TO THE CLAIMS

1. (currently amended) A pharmaceutical composition of matter in the form of a sterile injectable solution concentrate comprising a cyclosporin dissolved in dimethyl sulfoxide (DMSO) wherein the concentration of cyclosporin is from 0.1% to 90% by weight of the total composition, not intended for ophthalmic, cutaneous, oral or gavage application.

2. (previously presented) A composition as in claim 1 wherein the cyclosporin is cyclosporin A.

3. (currently amended) A method for administering cyclosporin into cerebrospinal fluid spaces of a patient, which comprises:

providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO sterile injectable solution by injection into the cerebrospinal fluid spaces to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

4. (currently amended) A method for administering a sterile injectable solution of cyclosporin by injection including ~~intra-ocular,~~ intravestibular, into or adjacent to the brain or spinal cord to a patient, the improvement which compromises: providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said sterile injectable solution of cyclosporin and DMSO ~~solution~~ by injection ~~intra-ocular,~~ intravestibular, into or adjacent to the brain, or spinal cord to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

5. (currently amended) A method for administering cyclosporin by injection including intravenous, intra-arterial or intraparenchymal, into a patient, the improvement which compromises: providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said sterile injectable solution of cyclosporin and DMSO ~~solution~~ by injection into intravenous, intra-arterial or intraparenchymal

spaces to said patient wherein said cyclosporin is present in an amount of from 0.1% to 90% by weight of the total composition.

6. (currently amended) A method for administering cyclosporin ~~orally,~~ inhalationally ~~rectally, vaginally, urethrally, bladder cisternally,~~or nasally to a patient, ~~intra-and peri-ocularly instillation by injection around the eye, within the eyeball, its structures and layers or dermally to a patient, the method comprising~~ the improvement which compromises: providing the cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution ~~orally,~~ inhalationally~~, rectally, vaginally, urethrally, bladder cisternally,~~ or nasally~~, intra and peri ocularly or dermally~~ to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

7. (previously presented) The method of claim 3 wherein the cyclosporin is cyclosporin A or a salt thereof.

8. (currently amended) An article of manufacture comprising packaging material and a sterile injectable pharmaceutical agent that is therapeutically effective for reducing or treating neuronal damage and for causing immunosuppression when administered by injection in a therapeutically effective quantity, wherein the packaging material comprises a label which indicates that the sterile injectable solution of pharmaceutical agent can be used for reducing or treating neuronal damage and for causing immunosuppression, and wherein said pharmaceutical agent comprises a sterile injectable solution of DMSO and one or more ~~cyclosporins,~~ cyclosporins, wherein said cyclosporins are present in an amount of from 0.1% to 90% by weight of the total composition ~~or salts thereof,~~ or a salt thereof, alone or in admixture with diluents or additives.

9. (currently amended) The article of manufacture according to claim 8, wherein the cyclosporin is cyclosporin A or a salt thereof.

10. (currently amended) The method according to claim 3 wherein the ~~administering~~ administration of a sterile injectable solution of cyclosporin into cerebrospinal fluid spaces is intraventricular or intrathecal.

11. (currently amended) ~~A method~~An improved method for treating Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV neuropathy, Guillain-Barré syndrome, neural transplantation, neural xenotransplantation, stroke, brain hemorrhage, brain and spine trauma, ionizing radiation, neurotoxicity of ~~vestibulocochlear~~vestibular structures, ~~and~~ or retinal detachment which comprises administering a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said sterile injectable solution of cyclosporin and DMSO solution to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

12. (currently amended) ~~A method~~ An improved method for inducing systemic immunosuppression in a patient with transplantation and autoimmune disease which comprises administering said sterile injectable solution of cyclosporin ~~dissolved in~~ and DMSO ~~in a pharmaceutically acceptable carrier, and administering said cyclosporine and DMSO solution~~ to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

13. (new) The pharmaceutical composition of matter as in claim 1 in the form of an intravestibularly injectable solution.

14. (new) The pharmaceutical composition of matter as in claim 1 in the form of an intraventricularly injectable solution.

15. (new) The pharmaceutical composition of matter as in claim 1 in the form of an intrathecaly injectable solution.

16. (new) The pharmaceutical composition of matter as in claim 1 in the form of an intravenously injectable solution.

17. (new) The pharmaceutical composition of matter as in claim 1 in the form of an intra-arterialy injectable solution.

18. (new) The pharmaceutical composition of matter as in claim 1 in the form of an intraparenchymally injectable solution.

19. (new) The pharmaceutical composition of matter as in claim 1 in the form of a solution adapted for injection into or adjacent the brain or spinal cord of a patient.

20. (new) The pharmaceutical composition of matter as in claim 1 in the form of a solution adapted for injection into cerebrospinal fluid spaces of a patient.